{
  "guideline": {
    "id": "PA166104995",
    "name": "Annotation of DPWG Guideline for metoprolol and CYP2D6",
    "source": "DPWG",
    "version": 35,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104995",
    "relatedChemicals": [
      {
        "id": "PA450480",
        "name": "metoprolol",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302533",
      "name": "Recommendation Annotation PA166302533",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104112,
        "html": "<p>Use the maximum dose for the relevant indication as a target dose.</p>\n<p>If the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative.</p>\n<p>Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</p>\n"
      },
      "implications": [
        "The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302524",
      "name": "Recommendation Annotation PA166302524",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104103,
        "html": "<p>If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA:</p>\n<ul>\n<li>Use smaller steps in dose titration and/or prescribe no more than 50% of the standard dose.</li>\n</ul>\n<p>OTHER CASES:</p>\n<ul>\n<li>No action required.</li>\n</ul>\n"
      },
      "implications": [
        "The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302537",
      "name": "Recommendation Annotation PA166302537",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104116,
        "html": "<p>Use the maximum dose for the relevant indication as a target dose.</p>\n<p>If the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative.</p>\n<p>Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</p>\n"
      },
      "implications": [
        "The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302528",
      "name": "Recommendation Annotation PA166302528",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104107,
        "html": "<p>The guideline does not provide a recommendation for metoprolol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on metoprolol."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302532",
      "name": "Recommendation Annotation PA166302532",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104111,
        "html": "<p>Use the maximum dose for the relevant indication as a target dose.</p>\n<p>If the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative.</p>\n<p>Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</p>\n"
      },
      "implications": [
        "The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302523",
      "name": "Recommendation Annotation PA166302523",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104102,
        "html": "<p>If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA:</p>\n<ul>\n<li>Use smaller steps in dose titration and/or prescribe no more than 50% of the standard dose.</li>\n</ul>\n<p>OTHER CASES:</p>\n<ul>\n<li>No action required.</li>\n</ul>\n"
      },
      "implications": [
        "The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302536",
      "name": "Recommendation Annotation PA166302536",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104115,
        "html": "<p>Use the maximum dose for the relevant indication as a target dose.</p>\n<p>If the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative.</p>\n<p>Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</p>\n"
      },
      "implications": [
        "The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302527",
      "name": "Recommendation Annotation PA166302527",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104106,
        "html": "<p>The guideline does not provide a recommendation for metoprolol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on metoprolol."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302531",
      "name": "Recommendation Annotation PA166302531",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104110,
        "html": "<p>Use the maximum dose for the relevant indication as a target dose.</p>\n<p>If the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative.</p>\n<p>Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</p>\n"
      },
      "implications": [
        "The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302522",
      "name": "Recommendation Annotation PA166302522",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104101,
        "html": "<p>If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA:</p>\n<ul>\n<li>Use smaller steps in dose titration and/or prescribe no more than 50% of the standard dose.</li>\n</ul>\n<p>OTHER CASES:</p>\n<ul>\n<li>No action required.</li>\n</ul>\n"
      },
      "implications": [
        "The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302535",
      "name": "Recommendation Annotation PA166302535",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104114,
        "html": "<p>Use the maximum dose for the relevant indication as a target dose.</p>\n<p>If the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative.</p>\n<p>Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</p>\n"
      },
      "implications": [
        "The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302526",
      "name": "Recommendation Annotation PA166302526",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104105,
        "html": "<p>The guideline does not provide a recommendation for metoprolol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on metoprolol."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302530",
      "name": "Recommendation Annotation PA166302530",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104109,
        "html": "<p>The guideline does not provide a recommendation for metoprolol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on metoprolol."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302521",
      "name": "Recommendation Annotation PA166302521",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104100,
        "html": "<p>If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA:</p>\n<ul>\n<li>Use smaller steps in dose titration and/or prescribe no more than 25% of the standard dose.</li>\n</ul>\n<p>OTHER CASES:</p>\n<ul>\n<li>No action required.</li>\n</ul>\n"
      },
      "implications": [
        "The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302534",
      "name": "Recommendation Annotation PA166302534",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104113,
        "html": "<p>Use the maximum dose for the relevant indication as a target dose.</p>\n<p>If the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative.</p>\n<p>Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</p>\n"
      },
      "implications": [
        "The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302525",
      "name": "Recommendation Annotation PA166302525",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104104,
        "html": "<p>If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA:</p>\n<ul>\n<li>Use smaller steps in dose titration and/or prescribe no more than 50% of the standard dose.</li>\n</ul>\n<p>OTHER CASES:</p>\n<ul>\n<li>No action required.</li>\n</ul>\n"
      },
      "implications": [
        "The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302538",
      "name": "Recommendation Annotation PA166302538",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104117,
        "html": "<p>Use the maximum dose for the relevant indication as a target dose.</p>\n<p>If the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative.</p>\n<p>Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</p>\n"
      },
      "implications": [
        "The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302529",
      "name": "Recommendation Annotation PA166302529",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450480",
          "name": "metoprolol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104108,
        "html": "<p>The guideline does not provide a recommendation for metoprolol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on metoprolol."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2024-03-25-16-13"
}